REDHILL BIOPHARMA overview

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, May 13, 2025 Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement , following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims...

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress PR Newswire RALEIGH, N.C., May 2, 2025 RedHill supports an independent medical education grant that includes a new two -part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes -- The first part of the program, led by a faculty of William Chey , MD, Vivian Asamoah , MD and Shailja Shah , MD, MPH, will...

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, April 28, 2025 Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant enhances RedHill's strategic...

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency PR Newswire TEL AVIV, Israel and RALEIGH, N.C., April 17, 2025 The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter TEL AVIV, Israel and RALEIGH, N.C. , April 17, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"),...

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption PR Newswire TEL AVIV, Israel and RALEIGH, N.C., April 16, 2025 GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models -- Novel mechanism of action, formulation and administration: Opaganib is a...

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights PR Newswire TEL AVIV, Israel and RALEIGH, N.C., April 10, 2025 Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global licensing deal (excluding North America ) with Hyloris Pharmaceuticals with RHB-102 for up to $60 million in potential milestone payments Approximately $8 million plus legal costs NY...

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation PR Newswire RALEIGH, N.C., March 18, 2025 RedHill plans to submit UK MAA 1 for Talicia for H. pylori infection, using MHRA's 2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG 3 Clinical Guideline as a first-line option, Talicia is the leading branded H. pylori therapy prescribed by U.S. gastroenterologists and the only FDA-approved all-in-one, low-dose...

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, March 12, 2025 The planned innovative Phase 2 study of RHB-204 1 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP 2 infection eradication utilizing novel endpoints and imaging, pending Type C discussions on...